Entresto (Sacubitril/Valsartan) Patent Expiration, LOE Window & CMS Spending

Entresto (Sacubitril/Valsartan) by Novartis: FDA Orange Book core substance LOE 2027-11-27 (last listed 2036-05-09), 16 AB generics, $4.64B 2024 CMS Part D & Medicaid spend, and 12 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovartis
FDA Application & PathwayN207620 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2027-11-27
Last Listed Patent or Exclusivity Date2036-05-09
Orange Book Patents (*PED Extensions)8 patents (2 *PED)
Active AB-Rated Generic Competitors16
2024 CMS Total Public Spend$4.64B
2024 Medicare Part D Spend$4.02B
2024 Medicaid Spend$624.3M
Reported Wholesale Price Change (CA SB 17)12 WAC filings (max 22.6% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.